In this sense, in the multicenter longitudinal registry study on the progression of patients with Raynaud’s phenomenon to systemic sclerosis (Very Early Diagnosis of Systemic Sclerosis Registry Study [VEDOSS]), the absence of baseline ANA was the most significant factor strongly associated with lack of progression within 5 years, with only about 11% of ANA-negative RP patients progressing to SSc [28]. The gene discussed is BTG3; the disease is systemic sclerosis.